Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary

Braveheart Bio (Nasdaq: BRVE) closed its upsized initial public offering, selling an aggregate 24,437,500 common shares at $18.00 per share, including 3,187,500 additional shares from the underwriters’ option.

The offering generated gross proceeds of approximately $439.9 million before expenses. All shares were sold by Braveheart Bio. The stock began trading on the Nasdaq Global Market on August 6, 2026 under ticker “BRVE”. Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel and Cantor served as joint book-running managers. The registration statements became effective with the SEC on August 5, 2026.

Positive

• Gross IPO proceeds of approximately $439.9 million before expenses
• Upsized IPO with 24,437,500 shares sold, including full over-allotment
• Shares priced at $18.00 and now trading on Nasdaq Global Market
• Strong syndicate of five joint book-running managers led the offering

Negative

• Issuance of 24,437,500 new shares increases share count and dilutes existing ownership

Market reaction after initial public offering closing: BRVE +4.60%

+4.60% $31.38

15m delay

+4.60% Vs previous close

$31.38 Last Price

$28.32 $32.99 Day Range

$2.22B Market Cap

0.2x Rel. Volume

Following this news, BRVE has gained 4.60%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $31.38.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

IPO shares: 24,437,500 shares IPO price: $18.00 per share Additional shares: 3,187,500 shares +3 more

6 metrics

IPO shares 24,437,500 shares Initial public offering

IPO price $18.00 per share Initial public offering

Additional shares 3,187,500 shares Full exercise of underwriters’ option

Gross proceeds $439.9 million Before underwriting discounts, commissions and offering expenses

Trading start date August 6, 2026 Shares began trading on Nasdaq Global Market

Registration effectiveness date August 5, 2026 Registration statements became effective

Key Terms

initial public offering, registration statements, prospectus, joint book-running managers

4 terms

initial public offering financial

"closing of its upsized initial public offering of an aggregate of 24,437,500 shares"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

registration statements regulatory

"Registration statements relating to the shares being sold in the initial public offering"

Registration statements are detailed documents companies file with securities regulators when they plan to offer shares or other securities to the public. They act like a recipe and instruction manual, listing a company’s business, finances, management, risks and how the offering will work, so investors can judge value and potential downsides. For investors, these filings provide the official, legally required facts needed to make informed decisions and spot warning signs.

prospectus regulatory

"The offering was made only by means of a prospectus"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

joint book-running managers financial

"acted as joint book-running managers for the offering"

Joint book-running managers are the lead banks or financial firms responsible for organizing and overseeing the sale of a large financial offering, such as a company’s stock or bonds. They coordinate efforts to set the price, attract investors, and ensure the offering is successful. Their role is important to investors because they help ensure the offering is well-managed, properly priced, and accessible to a wide range of buyers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced the closing of its upsized initial public offering of an aggregate of 24,437,500 shares of its common stock at an initial public offering price of $18.00 per share, including the full exercise by the underwriters of their option to purchase 3,187,500 additional shares. All shares of common stock were offered by Braveheart Bio. The shares began trading on the Nasdaq Global Market on August 6, 2026 under the ticker symbol “BRVE”.

The gross proceeds from the initial public offering, including full exercise of the underwriters’ option to purchase additional shares, before deducting underwriting discounts and commissions and offering expenses payable by Braveheart Bio, were $439.9 million.

Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel and Cantor acted as joint book-running managers for the offering.

Registration statements relating to the shares being sold in the initial public offering have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on August 5, 2026. The offering was made only by means of a prospectus, forming part of the effective registration statement relating to these shares. Copies of the final prospectus may be obtained from the SEC’s website at www.sec.gov and may also be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Braveheart Bio
Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity.

Investor Relations Contact
Alexander Sharif
New Street Investor Relations
Alexander@NewStreetIR.com

Media Contact
FGS Global
Braveheart-bio@fgsglobal.com 

FAQ

What were the final terms of the Braveheart Bio (NASDAQ: BRVE) IPO that closed on August 7, 2026?

Braveheart Bio’s IPO closed with 24,437,500 shares sold at $18.00 per share. According to Braveheart Bio, this included 3,187,500 shares from the underwriters’ fully exercised option and generated approximately $439.9 million in gross proceeds before underwriting discounts and offering expenses.

How much capital did Braveheart Bio (BRVE) raise in its upsized Nasdaq IPO?

Braveheart Bio raised about $439.9 million in gross proceeds from its IPO. According to Braveheart Bio, this figure includes the full exercise of the underwriters’ option to purchase additional shares, and is stated before deducting underwriting discounts, commissions, and offering-related expenses payable by the company.

At what price was the Braveheart Bio (BRVE) IPO priced and how many shares were issued?

The Braveheart Bio IPO was priced at $18.00 per share for 24,437,500 shares. According to Braveheart Bio, this total includes 3,187,500 additional shares sold after underwriters fully exercised their option, with all shares in the offering issued and sold by the company itself.

When did Braveheart Bio (NASDAQ: BRVE) begin trading its IPO shares on the Nasdaq Global Market?

Braveheart Bio shares began trading on the Nasdaq Global Market on August 6, 2026. According to Braveheart Bio, the common stock trades under the ticker symbol “BRVE” following the effectiveness of the company’s SEC registration statements on August 5, 2026.

Who were the underwriters for the Braveheart Bio (BRVE) initial public offering and what role did they play?

Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel and Cantor acted as joint book-running managers. According to Braveheart Bio, these banks underwrote and distributed the shares in the IPO, including managing the fully exercised option to purchase additional common stock.

What does the upsized initial public offering mean for Braveheart Bio (BRVE) shareholders?

The upsized IPO means Braveheart Bio sold more shares than initially planned, raising $439.9 million. According to Braveheart Bio, all 24,437,500 shares were newly issued by the company, which increases total share count and provides additional capital before offering-related costs are deducted.